Financing of Coloplast's acquisition of Kerecis


Financing of Coloplast’s acquisition of Kerecis

On 31 August 2023, Coloplast completed the acquisition of the Icelandic business Kerecis at an amount of approx. DKK 8.9bn. Kerecis is an innovative and fast-growing business within the biologics wound care segment and has developed a technology in which fish skin may be used as a method for wound care.

To begin with, the acquisition price was financed through a DKK 8.2bn bridge-to-equity loan, which was granted by Danske Bank A/S and Nordea Danmark, Fillial af Nordea bank Abp, Finland (as joint mandated lead arrangers, underwriters, bookrunner and original lenders).

Accura advised Danske Bank A/S and Nordea Danmark, Filial af Nordea Bank Abp, Finland in connection with the granting of and the payment under the bridge-to-equity loan.

Accura also advised the banks in connection with the following issue of new B shares in Coloplast.